Results 51 to 60 of about 1,973 (199)

Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) [PDF]

J Cosmet Dermatol
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1‐RAs), a class of drugs indicated for diabetes mellitus and weight control, have been implicated in alopecia. We mined data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to better understand the relationship between alopecia and GLP‐1‐RAs.
Gupta A, Teasell E, Bamimore M, Mirmirani P, Talukder M.   +4 more
europepmc   +2 more sources

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Introduction Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

Acta Dermato-Venereologica
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein   +7 more
doaj   +1 more source

Scale of Alopecia Areata Distress (SAAD‐41): Initial Validation Part 2—Scoring, Preliminary Reference Values and Validity

JEADV Clinical Practice, EarlyView.
The SAAD‐41 is a 41‐item scale developed to comprehensively assess Alopecia Areata psychosocial patient‐reported outcomes. Results support scoring the scale at the subdomain level and provisionally at the total‐score level. The total‐score can be calculated as a sum of the 41 SAAD items, with the sum referred to as the SAAD‐41‐Total.
Kristina Gorbatenko‐Roth, Mattea Trinitapoli, Sarah Wood, Irmina Wallander, Jaime Nugent, Maria Hordinsky   +5 more
wiley   +1 more source

Efficacy of oral tofacitinib in moderate to severe alopecia areata, totalis and universalis at the tertiary care hospital, Karachi

Journal of the Pakistan Medical Association
Objective: To evaluate the effectiveness and safety of oral tofacitinib in treating patients with different forms of alopecia. Method: The prospective, interventional, open-label study was conducted at the Department of Dermatology, Jinnah ...
Misbah Zari Qadir, Rabia Ghafoor, Muhammad Khurram Salahuddin, Parisa Sanawar, Nazia Jabeen, Khadija Asadullah   +5 more
doaj   +1 more source

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata. [PDF]

J Dermatol
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Ueki R, Mizuashi M, Harada K, Zhang X, Wu W, Chung WH, Kwon O, Luo X, Basey V, Wolk R, Shi N, Fujita K, Shen Y, Hirose T.   +13 more
europepmc   +2 more sources

Protective role of Nigella sativa in chemotherapy-induced alopecia

Bangladesh Journal of Pharmacology, 2017
Chemotherapy-induced alopecia affects the pathological as well as the psychological aspects of the cancer patient. In the present study, the protective role of Nigella sativa was evaluated in both adult and newborn albino rats. The anagen phase was first
Uzma Saleem, Shakila Sabir, Bashir Ahmad
doaj   +1 more source

Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years. Methods A cross‐sectional survey was conducted from August to September 2024 in a quota‐balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years ...
Rodney Sinclair, Samantha Eisman, Leona Yip, Maureen Hitschfeld, Anna Williamson, Giles Stratton, Christoph Lohan, Carol M. Y. Lee, Komal Kapoor, Candida da Fonseca Pereira   +9 more
wiley   +1 more source

Evidence Based Treatment of Alopecia Areata

Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2017
Background: Alopecia areata is a chronic autoimmune disease, involving non-scarring hair loss, which affects hair follicles and sometimes nails. Hair loss pattern presents as patchy alopecia, ophiasis, ophiasis inversa (sisapho), reticularis or diffuse ...
Eva Hariani, Nelva K. Jusuf
doaj   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source